Skip to search
Skip to main content
Back to Search
Start Over
Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Authors :
Barlesi, F. Wolf, J. Ahn, M-J. Doebele, R. C. Paz-Ares, L. Rolfo, C. Siena, S. Seto, T. Ohe, Y. Ou, S. H. I. Krebs, M. G. Kapre, A. Piault-Louis, E. McCallum, S. Osborne, S. Aziez, A. Drilon, A. Barlesi, F. Wolf, J. Ahn, M-J. Doebele, R. C. Paz-Ares, L. Rolfo, C. Siena, S. Seto, T. Ohe, Y. Ou, S. H. I. Krebs, M. G. Kapre, A. Piault-Louis, E. McCallum, S. Osborne, S. Aziez, A. Drilon, A.
Publication Year :
2020
Details
Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1238104631
Document Type :
Electronic Resource